AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 132 min read$AMRZ

Oran Baris purchased $284K of AMRZ

Oran Baris (Chief Financial Officer) purchased 6,000 shares of Amrize Ltd (AMRZ) at an average of $47.26 ($47.13–$47.38, $0.28M total) across 2 trades over 2026-08-11 to 2026-08-12.

Original reporting
SEC EDGAR · Oran Baris
Published Aug 13, 2026, 3:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 3:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AMRZ
Bullish
low confidence
Mentioned
$AMRZ
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZBullishLow
01

Why it matters

The newest fact is the CFO’s open-market purchase amount, price range, and timing, which may slightly influence sentiment but does not change fundamentals in the filing.

02

Market read

Traders may note the insider buying as a small positive sentiment datapoint, but there is no new guidance, contract, or earnings information.

03

What to watch

The article does not disclose whether the purchase was part of any broader compensation or tax-related activity, and it provides no performance or guidance context.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-13, covering purchases on 2026-08-11 to 2026-08-12

Background

This is an SEC Form 4 insider transaction disclosure for Amrize Ltd (AMRZ).

Company-level read

Ticker impact

$AMRZBullishLow confidence
Context

CFO Oran Baris filed a Form 4 open-market purchase of 6,000 AMRZ shares at about $47.13 to $47.38 per share.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a routine insider open-market purchase with no 10b5-1 plan and no accompanying operational or financial disclosure.

Market effects

Sector

No sector read-through is provided beyond a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider open-market buys can be driven by liquidity needs, diversification, or pre-existing personal plans, so the signal may be weak.

Key entities

  • issuer
    Amrize Ltd

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Oran Baris

    Chief Financial Officer who purchased AMRZ shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMRZ insider trading history →

Related articles

SEP 2
High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

investing.com2 min
SEP 2
$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

investing.com2 min
SEP 2
High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.

investing.com2 min